Study population characteristics
| Stage 1 | Stage 2 | Stage 3 | ||||
|---|---|---|---|---|---|---|
| Combined | Dream | ApotheekZorg | REF Col* | WTCCC | ReAct | |
| Number | 984 | 669 (69.7) | 315 (30.3) | 954 | 595 | 272 |
| Gender female (%) | 68.6 | 67.8 | 70.4 | 75.6 | 77.3 | 77.9 |
| Anti-TNF agent | ||||||
| Infliximab | 225 (22.9) | 225 (33.7) | 415 (43.5) | 268 (45.0) | ||
| Adalimumab | 638 (64.8) | 323 (48.2) | 315 (100) | 174 (18.2) | 68 (11.4) | 272 (100) |
| Etanercept | 121 (12.3) | 121 (18.1) | 365 (38.3) | 259 (43.6) | ||
| MTX co-medication (%) | 73.4 | 69.2 | 82.2 | 65.6 | 85.6 | 50 |
| DAS28 | ||||||
| Baseline | 5.5±1.2 | 5.3±1.3 | 5.8±1.0 | 5.5±1.2 | 6.7±0.9 | 5.9±1.0 |
| DeltaDAS (14 weeks) | 3.6±1.3 | 3.9±1.3 | 3.1±1.1 | |||
*The American College of Rheumatology Research and Education Foundation (REF) collection used for stage 2 is composed of nine different cohorts: Autoimmune Biomarkers Collaborative Network (ABCoN), Academic Medical Center Amsterdam (AMC), Behandelstrategieen voor Rheumatoide Arthritis (BeSt), Biological in Rheumatoid arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Birgham Rheumatoid Arthritis Sequential Study (BRASS),Epidemiological Investigation of Rheumatoid Arthritis (EIRA), Immunex Early Rheumatoid Arthritis (ERA) study, Karolinska Institutet (KI) study, Jan van Breemen Institute (READE) study, Treatment of Early Aggressive RA(TEAR).
Numbers are depicted as n (%) or mean±SD.
DAS, Disease Activity Score; MTX, methotrexate; TNF, tumour necrosis factor.